13F Pro

SEC Form 4 reporting owner

Fairmount Funds Management LLC

Fairmount Funds Management LLC has filed 35 Form 4 transactions reported between December 4, 2025 and September 9, 2026, as a reporting owner of Korsana Biosciences, Inc., Director of Apogee Therapeutics, Inc., Director of CRESCENT BIOPHARMA, INC., Director of Oruka Therapeutics, Inc., Director of Spyre Therapeutics, Inc., a reporting owner of Jade Biosciences, Inc., Director of Viridian Therapeutics, Inc.\DE, Director of Zenas BioPharma, Inc., Director of Cogent Biosciences, Inc. and a reporting owner of Damora Therapeutics, Inc..

Name as filed: Fairmount Funds Management LLC

Open-market buys, 24 mo
$63.0M
6 lines
Open-market sales, 24 mo
$660.6M
3 lines
Companies
10
with Form 4 filings
Latest transaction
Sep 9, 2026
transaction date

Roles and reported holdings

  • KRSAKorsana Biosciences, Inc.
    Sep 9, 2026

    Reporting owner

    No common-stock holding reported on a purchase, sale, gift or withholding line.

  • APGEApogee Therapeutics, Inc.
    Jan 22, 2026 – Sep 3, 2026

    Director

    Held indirectly (latest line)298,647 sh as of Jan 22, 2026 · Form 4

    24 months: $133.5M sold

  • CBIOCRESCENT BIOPHARMA, INC.
    Dec 4, 2025 – Jul 16, 2026

    Director

    Held indirectly (latest line)2,294,037 sh as of Jul 16, 2026 · Form 4

    24 months: $40.0M bought

  • ORKAOruka Therapeutics, Inc.
    Jun 2, 2026 – Jul 1, 2026

    Director

    No common-stock holding reported on a purchase, sale, gift or withholding line.

  • SYRESpyre Therapeutics, Inc.
    May 27, 2026 – Jun 23, 2026

    Director

    Held indirectly (latest line)0 sh as of Jun 23, 2026 · Form 4

    24 months: $399.7M sold

  • JBIOJade Biosciences, Inc.
    Jun 9, 2026

    Reporting owner

    No common-stock holding reported on a purchase, sale, gift or withholding line.

  • VRDNViridian Therapeutics, Inc.\DE
    May 11, 2026

    Director

    Held indirectly (latest line)5,090,928 sh as of May 11, 2026 · Form 4

    24 months: $20.0M bought

  • ZBIOZenas BioPharma, Inc.
    Mar 31, 2026

    Director

    Held indirectly (latest line)2,359,025 sh as of Mar 31, 2026 · Form 4

    24 months: $3.0M bought

  • COGTCogent Biosciences, Inc.
    Jan 22, 2026 – Mar 31, 2026

    Director

    Held indirectly (latest line)5,503,418 sh as of Jan 22, 2026 · Form 4

    24 months: $127.4M sold

  • DMRADamora Therapeutics, Inc.
    Feb 9, 2026 – Mar 23, 2026

    Reporting owner

    No common-stock holding reported on a purchase, sale, gift or withholding line.

Transaction history

All 35 reported transactions, newest first. Every row links to the Form 4 on SEC EDGAR.

DateCompanyTypeSharesValueFiling
Sep 9, 2026KRSAGrant or awardCode A · indirect48,445—Form 4
Sep 3, 2026APGEDirectorDisposition to issuerCode D · indirect7,657—Form 4
Sep 3, 2026APGEDirectorDisposition to issuerCode D · indirect14,461—Form 4
Sep 3, 2026APGEDirectorDisposition to issuerCode D · indirect10,370—Form 4
Sep 3, 2026APGEDirectorDisposition to issuerCode D · indirect47,758—Form 4
Sep 3, 2026APGEDirectorDisposition to issuerCode D · indirect6,743,321—Form 4
Sep 3, 2026APGEDirectorDisposition to issuerCode D · indirect51,166—Form 4
Sep 3, 2026APGEDirectorDisposition to issuerCode D · indirect340,855—Form 4
Aug 7, 2026APGEDirectorOption exerciseCode M · indirect10,370$455K@ $43.85Form 4
Aug 7, 2026APGEDirectorOption exerciseCode M · indirect31,838$541K@ $17.00Form 4
Jul 16, 2026CBIODirectorOpen-market purchaseCode P · indirect525,897$7.6M@ $14.50Form 4
Jul 16, 2026CBIODirectorOpen-market purchaseCode P · indirect853,450$12.4M@ $14.50Form 4
Jul 1, 2026ORKADirectorConversion of derivativeCode C · indirect42,641—Form 4
Jul 1, 2026ORKADirectorConversion of derivativeCode C · indirect3,553,410—Form 4
Jun 23, 2026SYREDirectorConversion of derivativeCode C · indirect16,667—Form 4
Jun 23, 2026SYREDirectorOpen-market saleCode S · indirect4,684,781$399.7M@ $85.31Form 4
Jun 23, 2026SYREDirectorConversion of derivativeCode C · indirect666,680—Form 4
Jun 9, 2026JBIOGrant or awardCode A · direct34,843—Form 4
Jun 9, 2026APGEDirectorGrant or awardCode A · indirect7,657—Form 4
Jun 2, 2026ORKADirectorGrant or awardCode A · indirect9,136—Form 4
Jun 2, 2026CBIODirectorGrant or awardCode A · indirect11,050—Form 4
May 27, 2026SYREDirectorGrant or awardCode A · indirect8,026—Form 4
May 11, 2026VRDNDirectorOpen-market purchaseCode P · indirect1,176,470$20.0M@ $17.00Form 4
Mar 31, 2026ZBIODirectorOpen-market purchaseCode P · indirect150,000$3.0M@ $20.00Form 4
Mar 31, 2026COGTDirectorConversion of derivativeCode C · indirect28,000—Form 4
Mar 31, 2026COGTDirectorConversion of derivativeCode C · indirect7,000,000—Form 4
Mar 23, 2026DMRAGrant or awardCode A · indirect37,313—Form 4
Feb 9, 2026DMRAOption exerciseCode M · indirect2,904—Form 4
Feb 9, 2026DMRAOption exerciseCode M · indirect5,809—Form 4
Feb 9, 2026DMRAOption exerciseCode M · indirect2,904,000—Form 4
Feb 9, 2026DMRAOption exerciseCode M · indirect5,809,000—Form 4
Jan 22, 2026COGTDirectorOpen-market saleCode S · indirect3,500,000$127.4M@ $36.40Form 4
Jan 22, 2026APGEDirectorOpen-market saleCode S · indirect1,750,000$133.5M@ $76.30Form 4
Dec 4, 2025CBIODirectorOpen-market purchaseCode P · indirect131,434$1.8M@ $13.41Form 4
Dec 4, 2025CBIODirectorOpen-market purchaseCode P · indirect1,360,000$18.2M@ $13.41Form 4

How this page is built

Every row comes from a Form 4 filed with the SEC, which officers, directors and holders of more than 10% of a company’s stock must file within two business days of a trade. Transactions are grouped by the reporting owner’s name as filed (spacing, capitals and punctuation ignored); two different people filing under an identical name would appear together, and one person filing under two spellings appears on two pages.

Open-market totals count code P purchases and code S sales over the last 24 months. The same trade reported on more than one filing is counted once; when another owner (for example a fund and its general partner) reports the identical trade, they are listed beside it. Holdings are the shares owned after the latest purchase, sale, gift or tax-withholding line, shown separately for direct and indirect ownership; an indirect figure is one holding line, not a total across every trust or entity.

This page describes what was filed with the SEC; it is not investment advice or a recommendation to buy or sell any security.